title: Novel target to kill CLL.
abstract: In this issue of Blood, Liu et al report on OSU-T315, a new agent that specifically disrupts the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) pathway and shows high proapoptotic activity against chronic lymphocytic leukemia (CLL) cells, which may indicate a potential therapeutic application in this disease
authors.affiliation: MEDICAL UNIVERSITY OF LODZ.
authors.forename: Tadeusz
authors.initials: T
authors.lastname: Robak
authors.affiliation: MEDICAL UNIVERSITY OF LODZ.
authors.forename: Piotr
authors.initials: P
authors.lastname: Smolewski
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000378:metabolism*; D051057:Proto-Oncogene Proteins c-akt / Q000037:antagonists & inhibitors*
chemical_list: D000970:Antineoplastic Agents; D051057:Proto-Oncogene Proteins c-akt